Home / Business and Economy / Lilly Narrows Obesity Drug Lead Over Novo
Lilly Narrows Obesity Drug Lead Over Novo
15 Sep
Summary
- Eli Lilly now holds over 30% of new US oral obesity treatment patients.
- Novo Nordisk previously claimed 90% of the oral obesity drug market.
- Oral obesity drugs could expand the market beyond injections.
Eli Lilly announced on September 14, 2026, that it has secured over 30% of new patients in the U.S. market for oral obesity treatments. This strategic gain challenges Novo Nordisk's early dominance with its Wegovy pill. Previously, Novo's CEO had estimated Wegovy held approximately 90% of this market, with Lilly's Foundayo as a competitor.
The increasing demand for oral obesity drugs is a key focus for investors. These treatments are appealing to patients who are hesitant about injectable therapies and may alleviate supply chain issues associated with them. Projections suggest oral drugs could represent over a third of GLP-1 weight-loss treatment usage by 2030.
Eli Lilly's injectable GLP-1 obesity treatment, Zepbound, is also performing well. It has shown preference among patients in the U.S. government's Medicare obesity drug pilot program, launched in July. A significant majority of patients in this program are new to weight-loss treatments.
Outside the U.S., Lilly faces competition from generic versions of Novo Nordisk's drugs in India and Canada, costing up to 70% less. However, Lilly notes that these market expansions have actually increased overall demand for their own treatments, such as Mounjaro, which is the brand name for tirzepatide in obesity and diabetes segments internationally.
